A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Inclusion Criteria

• •1. Subjects voluntarily participate in clinical research.
• •2. Age 18-70 years.
• •3. Adequate organ function at screening.
• •4. Clinical laboratory values meet criteria at screening visit.
• •5. Indications include:
• •MS;
• •1. Have been diagnosed of MS at least 6 months before screening.
• •2. Fulfill relapsed/refractory MS conditions.
• •NMOSD/MOGAD:
• •1. Have been diagnosed of NMOSD/MOGAD at least 6 months before screening.
• •2. AQP-4 IgG (NMOSD), or MOG-IgG (MOGAD) should be positive by CBA (Cell based transfection immunofluorescence assay).
• •3. Fulfill relapsed/refractory NMOSD/MOGAD conditions.
• •MG:
• •1. Have been diagnosed of MG at least 6 months before screening.
• •2. AChR-IgG or MuSK-IgG should be positive.
• •3. Fulfill relapsed/refractory NMOSD/MOGAD conditions.